Effect of Convalescent Plasma on Mortality among 1 Hospitalized Patients with COVID-19: Initial Three-2 Month Experience 3

Michael J. Joyner¹*, M.D., Jonathon W. Senefeld¹, Ph.D., Stephen A. Klassen¹, Ph.D., 4 John R. Mills², Ph.D., Patrick W. Johnson³, Elitza S. Theel², Ph.D., Chad C. Wiggins¹, 5 Ph.D., Katelyn A. Bruno⁴, Ph.D., Allan M. Klompas¹, M.B., B.Ch., B.A.O., Elizabeth R. 6 Lesser³, Katie L. Kunze⁵, Ph.D., Matthew A. Sexton¹, M.D., Juan C. Diaz Soto¹, M.D., 7 Sarah E. Baker¹, Ph.D., John R.A. Shepherd¹, M.D., Noud van Helmond⁶, M.D., Nigel 8 S. Paneth^{7,8#}, M.D., M.P.H., Ph.D., DeLisa Fairweather^{4#}, Ph.D., R. Scott Wright^{9,10#}, 9 M.D., Rickey E. Carter^{3#}, Ph.D., Arturo Casadevall^{11#}, M.D., Ph.D., *the US EAP COVID*-10 19 Plasma Consortium, 11

US EAP COVID-19 Plasma Consortium: Camille M. van Buskirk², M.D., Jeffrey L. 12

- Winters², M.D., James R. Stubbs², M.D., Robert F. Rea⁹, M.D., David O. Hodge³, Vitaly Herasevich¹, M.D., Ph.D., Emily R. Whelan⁴, Andrew J. Clayburn¹, Kathryn F. Larson⁹, 13
- 14
- M.D., Juan G. Ripoll¹, M.D., Kylie J. Andersen¹, Matthew R. Buras⁵, Matthew N.P. 15
- Vogt¹, M.D., Joshua J. Dennis¹, Riley J. Regimbal¹, Philippe R. Bauer¹², M.D., Ph.D., 16
- and Janis E. Blair¹³, M.D. 17

Affiliations: 18

- 19 ¹Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
- 20 ²Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- ³Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida 21
- 22 ⁴Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida
- ⁵Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona 23
- 24 ⁶Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University
- Health Care, Camden, New Jersey 25
- ⁷Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State 26
- 27 University, East Lansing, Michigan
- 28 ⁸Department of Pediatrics and Human Development, College of Human Medicine, Michigan
- 29 State University, East Lansing, Michigan
- 30 ⁹Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
- ¹⁰Human Research Protection Program, Mayo Clinic, Rochester, Minnesota 31
- ¹¹Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of 32
- Public Health, Baltimore, Maryland 33
- ¹²Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo 34 Clinic, Rochester, Minnesota
- 35
- ¹³Department of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Phoenix, 36
- Arizona 37

38 *Correspondence:

- 39 Michael J. Joyner, M.D., Department of Anesthesiology and Perioperative Medicine
- 40 Mayo Clinic | 200 First Street SW | Rochester, MN 55905
- 41 # Drs. Paneth, Fairweather, Wright, Carter and Casadevall contributed equally as senior authors
- 42 to the work of the study and manuscript.

43 Key Points

- 44 Question. Does transfusion of human convalescent plasma reduce mortality among
- 45 hospitalized COVID-19 patients?
- 46 Findings. Transfusion of convalescent plasma with higher antibody levels to
- 47 hospitalized COVID-19 patients significantly reduced mortality compared to transfusions
- 48 with low antibody levels. Transfusions within three days of COVID-19 diagnosis yielded
- 49 greater reductions in mortality.
- 50 **Meaning.** Embedded in an Expanded Access Program providing access to COVID-19
- 51 convalescent plasma and designed to assess its safety, several signals consistent with
- 52 efficacy of convalescent plasma in the treatment of hospitalized COVID-19 patients
- 53 emerged.

54 Abstract

Importance: Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease 2019 (COVID-19), but the efficacy remains uncertain.

59 **Objective:** To explore potential signals of efficacy of COVID-19 convalescent plasma.

60 **Design:** Open-label, Expanded Access Program (EAP) for the treatment of COVID-19

61 patients with human convalescent plasma.

62 **Setting:** Multicenter, including 2,807 acute care facilities in the US and territories.

Participants: Adult participants enrolled and transfused under the purview of the US
Convalescent Plasma EAP program between April 4 and July 4, 2020 who were
hospitalized with (or at risk of) severe or life threatening acute COVID-19 respiratory
syndrome.

Intervention: Transfusion of at least one unit of human COVID-19 convalescent plasma using standard transfusion guidelines at any time during hospitalization. Convalescent plasma was donated by recently-recovered COVID-19 survivors, and the antibody levels in the units collected were unknown at the time of transfusion.

71 Main Outcomes and Measures: Seven and thirty-day mortality.

72 **Results:** The 35,322 transfused patients had heterogeneous demographic and clinical 73 characteristics. This cohort included a high proportion of critically-ill patients, with 52.3% 74 in the intensive care unit (ICU) and 27.5% receiving mechanical ventilation at the time of 75 plasma transfusion. The seven-day mortality rate was 8.7% [95% CI 8.3%-9.2%] in patients transfused within 3 days of COVID-19 diagnosis but 11.9% [11.4%-12.2%] in 76 77 patients transfused 4 or more days after diagnosis (p<0.001). Similar findings were observed in 30-day mortality (21.6% vs. 26.7%, p<0.0001). Importantly, a gradient of 78 79 mortality was seen in relation to IgG antibody levels in the transfused plasma. For patients who received high IgG plasma (>18.45 S/Co), seven-day mortality was 8.9% 80 81 (6.8%, 11.7%); for recipients of medium IgG plasma (4.62 to 18.45 S/Co) mortality was 11.6% (10.3%, 13.1%); and for recipients of low IgG plasma (<4.62 S/Co) mortality was 82

13.7% (11.1%, 16.8%) (p=0.048). This unadjusted dose-response relationship with IgG
was also observed in thirty-day mortality (p=0.021). The pooled relative risk of mortality
among patients transfused with high antibody level plasma units was 0.65 [0.47-0.92]
for 7 days and 0.77 [0.63-0.94] for 30 days compared to low antibody level plasma
units.

88 **Conclusions and Relevance:** The relationships between reduced mortality and both 89 earlier time to transfusion and higher antibody levels provide signatures of efficacy for 90 convalescent plasma in the treatment of hospitalized COVID-19 patients. This 91 information may be informative for the treatment of COVID-19 and design of 92 randomized clinical trials involving convalescent plasma.

93 Trial Registration: ClinicalTrials.gov Identifier: NCT04338360

94 Introduction

Passive antibody transfer, including convalescent plasma or serum, has 95 previously been used to treat infectious diseases that involve the respiratory system ¹⁻³. 96 This therapeutic approach was established early in the last century and included 97 widespread use of convalescent plasma for treatment of the 1918 influenza⁴. In this 98 99 context, the coronavirus disease 2019 (COVID-19) pandemic has revived interest in the 100 use of convalescent plasma for the treatment of hospitalized patients with COVID-19. 101 Although there is substantial interest in the use of COVID-19 convalescent plasma, the efficacy signals are preliminary ^{5,6}. 102

103 In response to the global COVID-19 pandemic and need for access to treatments 104 possibly providing benefit while randomized clinical trials were in various stages of 105 development and enrollment, the Mayo Clinic initiated the US Expanded Access 106 Program (EAP) for convalescent plasma, which resulted in widespread use of 107 convalescent plasma to treat COVID-19 in the U.S. The EAP received collaborative and 108 financial support from the Biomedical Advanced Research and Development Authority (BARDA). Although the charter of the EAP was to provide access to and assess the 109 110 safety of COVID-19 convalescent plasma, we performed exploratory analyses on the 111 efficacy of this agent. We hypothesized, based on historical data that earlier 112 administration of convalescent plasma with high antibody levels would be associated 113 with reduced mortality. To address this hypothesis, we evaluated seven and 30-day mortality in 35,322 hospitalized adults transfused with COVID-19 convalescent plasma 114 115 by asking two questions. First, was earlier treatment of patients with convalescent 116 plasma after diagnosis of COVID-19 associated with reduced mortality compared to 117 later treatment in the course of disease? Second, were higher antibody levels in the 118 transfused convalescent plasma associated with reduced mortality?

119 Methods

120 Design and Oversight

As described previously^{7,8}, the EAP was a US Government-sponsored, national, pragmatic intervention conducted as a multicenter, open-label protocol in hospitalized adults with COVID-19. All hospitals or acute care facilities in the US and any physician licensed in the US were eligible to participate provided they agreed to adhere to the treatment protocol, FDA, and state regulations.

126 Mayo Clinic served as the academic research organization conducting the study. The 127 Mayo Clinic Institutional Review Board (IRB) was the central IRB, approved the protocol 128 all modifications, and performed regulatory oversight for all sites and investigators. The principal investigator served as the regulatory sponsor. A Data and Safety Monitoring 129 130 Board oversaw the safety analyses and advised the regulatory sponsor and the Mayo 131 Clinic IRB on risk. Written informed consent was obtained from the participant or a 132 legally-authorized representative prior to enrollment, except for those patients who 133 necessitated use of an emergency consent process defined in collaboration with the US 134 FDA.

135 Participants

Eligible patients were aged 18 years or older, hospitalized with a laboratory confirmed diagnosis of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and had (or were judged by a healthcare provider to be at high risk of progression to) severe or life-threatening COVID-19. Inclusion criteria and the clinical symptoms defining severe or life-threatening COVID-19 are outlined in **Supplement 1**.

141 Plasma Collection

142 Convalescent plasma was obtained from a registered or licensed blood collector, and 143 COVID-19 antibody levels were unknown at the time of plasma collection. Convalescent 144 plasma was donated by COVID-19 survivors with confirmed diagnosis via clinical 145 laboratory test whom were symptom free for 14 days, or more according to standard 146 blood center procedures⁹. An aliquot of plasma or serum was shipped from a subset of 147 blood collection centers for later antibody testing. At the time of collection, each plasma

unit was assigned a standardized identifying number (ISBT 128 code) specific to the
 donor, which was used to link antibody levels with study outcomes corresponding to the
 plasma *recipient(s)*.

151 Plasma Transfusion

152 Compatible COVID-19 convalescent plasma was administered intravenously according 153 to individual institutional protocols. The transfusion dose of COVID-19 convalescent 154 plasma was at least one unit (approximately 200 mL), with the option to administer 155 additional doses if clinically justified.

156 Data Entry

157 Web-based, standardized data reporting surveys were completed to assess the clinical 158 status of patients using the Research Electronic Data Capture system (REDCap, v.9.1.15 Vanderbilt University, Nashville, TN)^{10,11}, with FDA authorization, as previously 159 described^{7,8}. Given the rapidity at which the EAP was implemented and considering the 160 161 stress on clinical staff at participating sites during this on-going pandemic, the webbased case reporting forms were designed to optimize convenience. Additionally, 162 163 although the patient inclusion criteria were specific to hospitalized patients, these 164 criteria were exceptionally broad (Supplement 1). While these elements of the EAP 165 may be atypical, they are perhaps understandable in a crisis of the magnitude of the 166 COVID 19 pandemic.

167 Antibody testing

Binding antibody levels from sera were tested using the Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG chemiluminescent immunoassay (CLIA) in accordance with manufacturer instructions¹². The Ortho-Clinical IgG CLIA is a qualitative assay based on a recombinant form of the SARS-CoV-2 spike subunit 1 protein. Results of this assay are based on the sample signal-to-cut-off (S/Co) ratio, with values <1.0 and \geq 1.00 corresponding to negative and positive results, The S/Co values reflect relative levels of anti-SARS-CoV-2 antibodies.

175 Statistics

176 The sample size for the EAP was not determined a priori and patient accrual has not 177 concluded at the time of this writing. The sample sizes for these analyses varied by the 178 availability of linked antibody data, and in some cases, missing data. For the analyses 179 not associated with antibody data, all transfusions on or before July 4, 2020 were 180 included (i.e., three months after the first confirmed transfusion in the EAP). The 181 database was locked for this study report on August 5, 2020 to allow all included 182 patients to have up to 30 days of follow up after transfusion. For the subset of patients 183 with remnant samples suitable for antibody analysis, all patients matched by the 184 standardized identifying number (ISBT 128 code) were included, with some caveats detailed below. 185

186 Based on insights from the pre-antibiotic era that antibody therapy was most effective when given early^{2,13}, our cohort was stratified into categories based on the days from 187 COVID-19 diagnosis to plasma transfusion, including: 0, 1-3, 4-10, and 11 or more days 188 189 and for some graphical presentations and analyses, dichotomized into 0-3 vs. 4 or more 190 days. The timing of death was recorded within the precision of a calendar day, so 191 adjustments were needed to develop survival estimates. For deaths that occurred on 192 the same day of plasma transfusion, a death indicator representing 0.5 days was 193 assigned. Otherwise, the number of days between plasma transfusion and death was 194 calculated for each patient. Transfused patients were assumed to be alive unless death 195 was recorded via web-based reporting survey.

196 Given that patients may have had more than one unit of plasma from different donors 197 and the days from diagnosis to transfusion were heterogeneous, decision rules were required for analyses of the antibody data. To control for the potential confounding 198 199 effects of plasma volume and non-uniform antibody levels between multiple plasma 200 units in the analysis, plasma recipients with a single unit, defined as 150 - 250 mL of 201 plasma, were included in the analysis. Finally, plasma from a single donor may have 202 been fractioned into multiple plasma units and transfused to multiple recipients. The analysis did not adjust for the potential clustering that may have occurred in doing so. 203 204 For the semi-quantitative Ortho-Clinical IgG assay, low, medium and high relative

binding antibody levels were established by setting thresholds for low and high based on the $\sim 20^{\text{th}}$ and $\sim 80^{\text{th}}$ percentiles of the distribution for the S/Co ratios, respectively. Accordingly, the thresholds were set at 4.62 S/Co and 18.45 S/Co.

Unadjusted (crude) mortality and adjusted mortality estimates were constructed. For the unadjusted mortality, or case fatality rate, tabulations of the number of mortality events recorded divided by the total number at risk were computed. Score confidence intervals were estimated. For analysis within subgroups, crude mortality was also estimated by grouping the events on key strata variables (e.g., time to transfusion; time epoch of the study)

214 With the study being non-randomized and containing multiple sources of possible 215 confounding, adjusted estimates of point mortality were also estimated. Two 216 approaches to adjusting for confounding were implemented. First, the general process 217 of generating crude estimates by strata was used to estimate the relative risk by stratum and then a pooled (common) estimate over all strata was estimated using the Mantel-218 219 Haenszel estimator. The second approach for adjusted point estimates was developed 220 as an extension of the methods used for estimating adjusted survival, using a baseline 221 Cox regression model fitted to the data. Without loss of generality, we assumed a 222 single variable of direct interest (e.g., days to transfusion) and a set of covariates to be 223 controlled for within the estimate. Using the 'conditional' method for estimating adjusted survival curves¹⁴, an adjusted estimate of the mortality at Day 7, for example, was 224 225 obtained. To estimate the confidence interval for the adjusted survival curve, the 226 bootstrap method was used. For each of the bootstrap replicates, the original full data 227 set was used to determine the reference distribution for standardization of the mortality 228 estimate. This approach was extended to provide an estimate of the relative risk over 229 one or more variables of interest. The posterior distribution of potential relative risks was constructed by a Cartesian merge of the posterior adjusted survival estimates for each 230 group. The 2.5th and 97.5th percentiles of this distribution were used as the bootstrap 231 confidence interval for the relative risk. No p-values were provided for this method. The 232 233 adjustment variables used in these analyses were as follows: time epoch (as shown in 234 **Table 1**), gender, race, age at enrollment (as categories), and indicator variables for having already developed one or more severe COVID-19 conditions (as shown in **Table**1), being on a ventilator, use of hydroxychloroquine, use of remdesivir, and use of
steroids prior to transfusion.

Descriptive statistics are presented as frequencies and percentages. Analytic data are presented as point estimates and 95% confidence intervals. P-values less than 0.05 were considered statistically significant and no correction for multiple testing has been applied to reported p-values. All statistical analyses were completed using R version 3.6.2.

243 **Results**

244 Patient Characteristics

Between April 4 and July 4, 2020, 47,047 patients were enrolled in the EAP, of whom 245 36,226 were transfused with COVID-19 convalescent plasma. Of the 1,959 registered 246 247 sites with at least one patient enrolled, 1,809 sites had transfused at least one patient 248 (92.3%) and 928 sites had transfused at least ten patients (47.4%), Figure 1. Data were included for 35,322 transfused patients with 7-day and 30-day follow-up. Key patient 249 250 characteristics are presented in **Table 1**, stratified into three groups delineating the time 251 period of the study and COVID-19 pandemic. The data set represented a non-252 probability sample of hospitalized COVID-19 patients with diverse representation of 253 gender, age, weight status, race, and ethnicity. As shown in **Table 1**, the patients 254 transfused early in the study period (before May 01) were more critically-ill (higher rates 255 of mechanical ventilation, ICU admissions and septic shock), had higher concomitant 256 treatment with hydroxychloroquine and azithromycin, and lower concomitant treatment with remdesivir compared with groups transfused later in the study period. 257

258 Unadjusted Analyses

Since the initiation of the EAP, there has been a reduction in both the seven-day crude 259 260 mortality rate and a pronounced shift of the time to transfusion towards more rapid transfusion of convalescent plasma. The crude seven-day mortality rate was reduced in 261 262 patients transfused within 3 days (8.7%, 8.3%-9.2%) of COVID-19 diagnosis compared 263 to patients transfused 4 or more days after COVID-19 diagnosis (11.9%, 11.4%-12.3%; 264 P<0.001), Table 2. Similar trends were seen for unadjusted 30-day mortality. Table 2 265 presents several additional analyses by risk modifiers (e.g., age and ventilation status at time of transfusion). As a means for controlling for study epoch, the time to transfusion 266 267 association is presented further stratified by study period. More favorable estimates for 268 mortality were found for all early transfusions (3 or fewer days) across both 7- and 30-269 day mortality for all three study months (*P*<0.001; **Table 2**).

270 Adjusted Analysis including Antibodies

In a subset of 3,082 transfused patients who received only a single unit of plasma (150 – 250 mL), the unadjusted antibody association with mortality is presented in **Table 2**.

273 Supplemental Table 2 presents the key demographic data by antibody groups (low, medium and high) for these patients. While there were some statistically significant 274 275 differences among the antibody level groupings, this table shows that patients were well balanced across the antibody level groupings as a whole. The associations of mortality 276 277 with antibody levels was found at both 7- and 30-days (p<0.05 for both) and when 278 antibody levels were stratified by time to transfusion, a pronounced separation in 279 mortality was found between the extremes of the classification (early transfusion, high 280 antibody levels vs. late transfusion, low antibody levels) albeit the associations for 7-day 281 mortality was at the threshold for statistical significance (p=0.05). Supplemental Table 282 2 presents additional estimates of crude mortality on the subset of patients with 283 matched antibody data.

Figure 2A presents the adjusted analyses with antibody groupings alone whereas **Figure 2B** presents these same data allowing for the timing of the transfusion to be integrated directly into the analysis. These data demonstrate a clear "dose" dependent relationship of reduced 7-day mortality with the higher antibody levels. **Figure 2C** and **2D** replicate these findings using 30-day mortality data. While some confidence intervals include the null value of relative risk of 1.0, the magnitude of relative risks, particularly after adjustment, is an important finding of the study.

291 **Figure 3** presents an alternate analytical approach to estimate the effect of the antibody 292 levels. The stratified Mantel-Haenszel approach estimates the relative risk for both 7-293 and 30-day mortality for patient profiles in the analysis. This stratification approach 294 provides direct analytical control for the potential confounders as each row in the figure 295 represents homogeneity with respect to the factors listed. Overall, there is a consistent 296 signal of a protective effect of the high antibody levels across the strata. The pooled, or 297 common, relative risk for 7-day and 30-day mortality were 0.65 (0.47 to 0.92) and 0.77 (0.63 to 0.94). For this analysis only patients transfused with units containing antibody 298 299 levels over 18.45 S/Co or less than 4.62 S/Co were included.

300 Discussion

In our cohort of over 35,000 hospitalized patients with COVID-19, several signals 301 302 consistent with effectiveness for convalescent plasma were observed in a broad sample 303 of acute care facilities across the US. Earlier use of convalescent plasma was 304 associated with lower observed rates of 7-day and 30-day mortality. The use of 305 convalescent plasma with higher antibody levels was associated with reduced 7-day 306 and 30-day mortality. These findings were supported by two different analytical methods 307 used to control for confounding. The finding of a dose response between antibody levels 308 and reduction in mortality provides strong evidence that specific antibody is the active 309 agent in convalescent plasma for treatment of COVID-19. All data considered as a 310 whole, these findings are consistent with the notion that the quality and manner in which 311 convalescent plasma is administered to patients hospitalized with COVID-19 may 312 reduce mortality.

313 Given the historical efficacy of passive antibody therapy for infectious diseases, the primary objective of the EAP was to facilitate access to convalescent plasma for 314 hospitalized COVID-19 patients across the US. The other major goal was to assess 315 safety. With these goals met^{7,8}, we analyzed the data from 1,809 sites and noted there 316 was variability in time to transfusion after diagnosis. Initially, we had no information 317 318 about the antibody levels in the convalescent plasma being administered. These 319 factors provided elements of inherent randomization in the data collected and formed 320 the basis of an exploratory analysis for signals associated to efficacy. They are also 321 consistent with key principles of antibody therapy recognized during the heyday of this treatment modality in the 1920s and 30s^{15,16}, supporting their use as a framework to 322 explore the efficacy of convalescent plasma in COVID-19. 323

324 Time to Treatment

Both 7-day and 30-day mortality adjusted for disease severity and demographic factors were reduced in patients transfused within 3 days of COVID-19 diagnosis compared to patients transfused 4 or more days after COVID-19 diagnosis. Additionally, the declining week-to-week trends in crude mortality (as previously observed⁷) were temporally associated with more rapid treatment. Prior to the antibiotic era, treatment of respiratory

infections with antibody therapy was most effective if initiated within three days of hospitalization. Thus, we used a similar timeframe, relative to date of diagnosis rather than hospitalization, for stratifying the current data. Along similar lines, 7 and 30 day survivors received on average higher volumes of plasma in unadjusted analyses. This is of interest because we had no knowledge of the volume of plasma which might constitute an efficacious dose prior to beginning this study.

336 Antibody Assessment

337 Seven and 30 day mortality rates were reduced in patients who received plasma with 338 higher antibody levels. This finding is more limited than the time data as only a subset of 339 the plasma units had remnant samples preserved that were suitable for assaying 340 antibody levels. The survival benefit became more pronounced when the analysis was 341 restricted to less severely ill patients treated early. Because of the multifactorial nature 342 of antibody-mediated effects and the potential for other disease modifying factors to be 343 present in convalescent plasma, further assay development to more fully characterize 344 the mechanisms in which plasma confers anti-viral properties is warranted. We also 345 note that there was no evidence of worsening outcomes or increased mortality in 346 patients treated with very high antibody levels indicating that antibody dependent 347 enhancement of disease was unlikely. Finally, it is important to recognize that the 348 antibody levels we obtained were on repurposed remnant biospecimens collected for 349 blood banking quality assurance. Thus there was potential variability in a number of 350 factors related to biospecimen handling and storage that might influence the 351 measurement of antibody levels in the specimens available to us. Of note adjusted 30-352 day mortality was 30% in patients treated with plasma with low antibody levels (IgG) 4 353 or more days after COVID-19 diagnosis. By contrast 30-day mortality was 20% in patients treated within 3 days of diagnosis with plasma with high antibody levels. The 354 pooled estimate from the stratified analysis estimated a 23% relative reduction in 355 mortality at 30 days across a wide range of sub-strata within the study. This reduction in 356 357 mortality is similar to that observed in a number of small randomized trials and retrospective matched control studies¹⁷. 358

359 Limitations

360 The design of the EAP has been criticized because it was not a randomized placebo, controlled trial (RCT)¹⁸. We started the EAP in late March 2020. It was designed to 361 provide access to convalescent plasma largely at hospitals and acute care facilities that 362 363 were not already part of a RCT or did not have the infrastructure to support complex 364 RCTs. We also envisioned modest total enrollment and our original IRB approval was 365 for 5,000 patients. In this context, our primary goal was to report on the safety of 366 convalescent plasma and to perform an exploratory analysis for potential signals of 367 efficacy. As described earlier, the EAP was a pragmatic study design, organized to 368 allow routine clinical care to dictate the timing and administration of plasma with the 369 collection of real world data. We did not prespecify which medications patients should 370 be on to participate. The enrollment and data collection forms were streamlined to make 371 participation easy for sites engulfed in the work of a pandemic. The use of a central, 372 academic IRB allowed for consistent data evaluation and oversight. We streamlined PI 373 credentialing and IRB reliance processes. All forms were web-based at a time when 374 some believed that SARS-CoV-2 might be transmitted via paper contaminated with the 375 virus. We did not randomly assign treatment strategies or use of adjunctive medications. 376 Nonetheless, there were some elements of randomization or pseudo-randomization in 377 our study. Physicians could choose the timing of convalescent plasma, the number of units administered, any repeat therapies and whether ICU or mechanically ventilated 378 379 patients were included. Furthermore, the degree of immune activity within the units of 380 convalescent plasma (i.e. specific IgG levels) was not known. It was assumed that 381 patients would receive plasma with low, medium and high antibody levels in a pseudo-382 randomized manner and that would enable assessment of efficacy.

We acknowledge that RCTs produce evidence of the highest quality in most but not all clinical situations. RCTs can occur when a number of specific criteria are present which allow their conduct. First, RCTs necessitate a stable supply of investigational product (i.e. convalescent plasma) or placebo/comparator which can be pre-positioned at all participating sites. The supply of convalescent plasma in April was not sufficient for such collection and pre-positioning. Second, RCTs require sufficient numbers of sites which have an appropriate patient base to approach for the study. The COVID-19

390 pandemic has migrated across different US regions every few weeks, making it 391 challenging to predict where sites should be selected and prepared for a RCT. Third, 392 sites must be validated and activated. This work requires training of the investigators 393 and study team members as well as typically on-site visits. The crises of the COVID-19 394 pandemic were not compatible with these site training and activation activities; travel 395 within the US has been restricted and staff sent to activate sites would likely have been 396 quarantined for two weeks before being able to go to another region to activate sites. 397 Fourth, the very nature of a RCT requires subject willingness to be randomized to active 398 treatment or placebo or a comparator agent. There was no consensus in April nor is 399 there a global consensus now regarding what would be an appropriate placebo-control 400 to use. Fifth, many COVID-19 patients would likely have been distrustful of being 401 randomized to a placebo based upon historical precedent. Sixth, the number of sites 402 who could have participated in a RCT is limited; who was the appropriate ethical entity to pick those sites and to exclude other sites? Our design allowed any willing hospital, 403 404 PI and patient to be included in the pragmatic, real-world data study. Finally, there were 405 ongoing small RCTs when we started this program. Physicians, hospitals and patients 406 have the choices of this program versus a RCT. It is clear that over 90,000 patients and 407 over 10,000 physicians elected to participate in the pragmatic, real-world evidence 408 study design. We did not indicate our study would prove efficacy or even offer potential 409 help. It was clear that it was a research investigation and informed consent was 410 obtained in all subjects prior to the transfusion of plasma. Perhaps the current design 411 can inform trialists and RCT advocates of the importance of study designs which are 412 easy and simple to join/enroll and which make the workload of participation as easy and 413 clinically relevant as possible.

414 Conclusion

The relationships between mortality and both time to plasma transfusion, and antibody levels provide a signature that is consistent with efficacy for the use of convalescent plasma in the treatment of hospitalized COVID-19 patients.

418 Disclaimer

The views and opinions expressed in this manuscript are those of the authors and do not reflect the official policy or position of the US Department of Health and Human services and its agencies including the Biomedical Research and Development Authority and the Food and Drug Administration, as well as any agency of the U.S. government. Assumptions made within and interpretations from the analysis are not reflective of the position of any US government entity.

425 Acknowledgements: We thank the dedicated members of the US Convalescent 426 Plasma Expanded Access Program team— Machiko Anderson, Supriya Behl, Lori 427 Bergstrom, Zachary Buchholtz, Brian Butterfield, Isha Chekuri, Joshua Culberson, Grant 428 Dubbels, Adam Eggert, Ree Erickson, Rebekah Frost, Daniel Gaz, Winston Guo, Starr 429 Guzman, Karina Hex, Vidhu Joshi, Megan Knudson, Tessa Kroeninger, Frances Lynch, 430 Tim Miksch, Lisa Muenkel, Ryan Oldenburg, Amy Olofson, Laura Pacheco-Spann, Dr. Kelly Paulson, Dr. Sumedha Penheiter, Melanie Peterson, Katrina Pierce, Michaela 431 432 Pletsch, Nicloas Saikali, Jeffrey Schmoll, Pamela Skaran, Lindsay Stromback, Edward 433 Swaray, Morgan Swope, Kristine Tree, Joe Wick, Janelle Worthington. We thank the members of the Mayo Clinic Institutional Review Board, the Mayo Clinic Office of 434 435 Human Research Protection, the Mayo Clinic Office of Research Regulatory support and in particular Mark Wentworth, the Executive Dean of Research at Mayo Clinic Dr. 436 437 Gregory Gores and the CEO of Mayo Clinic Dr. Gianrico Farrugia for their support and 438 assistance, and the independent Data and Safety Monitoring Board for their work and 439 oversight of the Expanded Access Program— Dr. Allan S. Jaffe (chair), Dr. David O. 440 Warner, Dr. William G. Morice II, Dr. Paula J. Santrach, Dr. Robert L. Frye, Dr. Lawrence J Appel, Dr. Taimur Sher. We thank the members of the National COVID-19 441 Convalescent Plasma Project (http://ccpp19.org) for their intellectual contributions and 442 support. We thank the participating medical centers and medical teams, and blood 443 444 centers for their rigorous efforts necessary to make this program possible. We also 445 thank the donors for providing COVID-19 convalescent plasma.

446 **Contract and Grant Support:** This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary 447 for Preparedness and Response; Biomedical Advanced Research and Development 448 449 Authority under Contract No. 75A50120C00096. Additionally, this study was supported 450 in part by National Center for Advancing Translational Sciences (NCATS) grant 451 UL1TR002377, National Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 452 (to MJJ), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5T32DK07352 (to JWS and CCW), Natural Sciences and Engineering Research 453 Council of Canada (NSERC) PDF-532926-2019 (to SAK), National Institute of Allergy 454 and Infectious Disease (NIAID) grants R21 AI145356, R21 AI152318 and R21 455 AI154927 (to DF), R01 AI152078 9 (to AC), National Heart Lung and Blood Institute 456 RO1 HL059842 (to AC), National Institute on Aging (NIA) U54AG044170 (to SEB), 457 Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health 458 459 Basketball Association (NBA), Millennium Pharmaceuticals, Group. National 460 Octapharma USA, Inc, and the Mayo Clinic.

461 References

- Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. *Crit Care Med.* 2010;38(4 Suppl):e66-73.
- 465
 465
 466
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
 467
- 468 3. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. *Clin Infect Dis.* 1995;21(1):150-161.
- 4. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood
 471 products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med.*472 2006;145(8):599-609.
- 473 5. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical
 474 Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized
 475 Clinical Trial. JAMA. 2020.
- 476 6. Salazar E, Perez KK, Ashraf M, et al. Treatment of Coronavirus Disease 2019 (COVID477 19) Patients with Convalescent Plasma. *Am J Pathol.* 2020.
- 478 7. Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update: COVID-19 Convalescent
 479 Plasma in 20,000 Hospitalized Patients. *Mayo Clinic Proceedings*. 2020;in press.
- 480 8. Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19
 481 convalescent plasma in 5000 patients. *J Clin Invest.* 2020.
- Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the
 prevention and treatment of COVID-19. *J Clin Invest.* 2020.
- 484 10. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform.* 2019;95:103208.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42(2):377-381.
- Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four High Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. *J Clin Microbiol.* 2020;58(8).
- 493 13. Flexner S. The Results of the Serum Treatment in Thirteen Hundred Cases of Epidemic
 494 Meningitis. *J Exp Med.* 1913;17(5):553-576.
- 495 14. Therneau TM, Crowson CS, Atkinson EJ. Adjusted survival curves. In: January; 2015.
- 496 15. Casadevall A, Scharff MD. "Serum Therapy" revisited: Animal models of infection and
 497 the development of passive antibody therapy. *Antimicrob Agents Chemotherap.*498 1994;38:1695-1702.
- 49916.Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in
infectious diseases. *Clin Infect Dis.* 1995;21:150-161.
- 501 17. Joyner MJ, Klassen SA, Senefeld JW, et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy *in review.* 2020.
- 503 18. Califf RM, Hernandez AF, Landray M. Weighing the Benefits and Risks of Proliferating
 504 Observational Treatment Assessments: Observational Cacophony, Randomized
 505 Harmony. JAMA. 2020.

506

Table 1. Patient Characteristic	cs Stratified by Time Po	eriod of COVID-19 Conv	valescent Plasma Tran	sfusion.	
	Apr 04 - May 01	May 01 - Jun 04	Jun 04 - Jul 04	Total Patients	Divoluo
	(N=6,990)	(N=14,846)	(N=13,486)	(N=35,322)	P value
Age at Enrollment (years)					<0.001
18 to 39	539 (7.7%)	1,337 (9.0%)	1,596 (11.8%)	3,472 (9.8%)	
40 to 59	2,424 (34.7%)	4,938 (33.3%)	4,806 (35.6%)	12,168 (34.4%)	
60 to 69	2,007 (28.7%)	3,791 (25.5%)	3,170 (23.5%)	8,968 (25.4%)	
70 to 79	1,358 (19.4%)	2,879 (19.4%)	2,467 (18.3%)	6,704 (19.0%)	
80 or older	662 (9.5%)	1,901 (12.8%)	1,447 (10.7%)	4,010 (11.4%)	
Gender					<0.001
Female	2,546 (36.5%)	5,961 (40.2%)	5,489 (40.8%)	13,996 (39.7%)	
Male	4,416 (63.4%)	8,838 (59.7%)	7,961 (59.1%)	21,215 (60.2%)	
Undisclosed	6 (0.1%)	11 (0.1%)	11 (0.1%)	28 (0.1%)	
Weight Status					<0.001
Underweight	69 (1.2%)	286 (1.9%)	156 (1.2%)	511 (1.5%)	
Normal Weight	1,010 (17.4%)	2,601 (17.6%)	1,744 (12.9%)	5,355 (15.7%)	
Overweight	1,723 (29.7%)	4,096 (27.8%)	3,647 (27.1%)	9,466 (27.8%)	
Obese	2,997 (51.7%)	7,761 (52.6%)	7,926 (58.8%)	18,684 (54.9%)	
Race					<0.001
White	3,330 (47.6%)	7,299 (49.2%)	7,178 (53.2%)	17,807 (50.4%)	
Asian	456 (6.5%)	628 (4.2%)	390 (2.9%)	1,474 (4.2%)	
Black or African	1 301 (18 6%)	2 971 (20 0%)	2 379 (17 6%)	6 651 (18 8%)	
American		2,011 (201070)	2,010 (11.070)		
Other or Unknown	1,903 (27.2%)	3,948 (26.6%)	3,539 (26.2%)	9,390 (26.6%)	
Ethnicity					<0.001
Hispanic/Latino	2,391 (34.2%)	5,297 (35.7%)	5,875 (43.6%)	13,563 (38.4%)	
Not Hispanic/Latino	4,599 (65.8%)	9,549 (64.3%)	7,611 (56.4%)	21,759 (61.6%)	
Clinical Status					
Current severe or life-	5.584 (79.9%)	9.761 (65.7%)	8,157 (60,5%)	23,502 (66,5%)	<0.001
threatening COVID-19		-, - (,	-, - ()		
Intensive Care Unit	4 004 (05 00/)	7 000 (52 20()		40 404 (50 00()	.0.004
(ICU) care prior to	4,601 (65.8%)	7,908 (53.3%)	5,952 (44.1%)	18,461 (52.3%)	<0.001
Mechanical Ventilation					
prior to infusion	3,217 (49.9%)	4,143 (27.9%)	2,213 (16.4%)	9,573 (27.5%)	<0.001
Severe Risk Factors ^a					
Respiratory failure	4 063 (72 8%)	6 352 (65 1%)	4 760 (58 4%)	15 175 (64 6%)	<0.001
Dyspnea	3 543 (63 4%)	6 976 (71 5%)	6 476 (79 4%)	16,995 (72,3%)	<0.001
Blood oxygen saturation	0,010 (00.170)	0,010 (111070)	0,110(10.170)	10,000 (121070)	
≤ 93%	3,507 (62.8%)	7,063 (72.4%)	6,394 (78.4%)	16,964 (72.2%)	<0.001
Lung infiltrates > 50%	0.445 (40.00()	4 454 (40 50()	0.045 (07.00()	0.504 (40.00()	0.004
within 24 to 48 hours	2,415 (43.2%)	4,151 (42.5%)	3,015 (37.0%)	9,581 (40.8%)	<0.001
Respiratory frequency ≥	2 205 (20 5%)	1 171 (12 00/)	2 266 (44 20/)	0 745 (41 59/)	-0.001
30/min	2,205 (39.5%)	4,174 (42.0%)	3,300 (41.3%)	9,745 (41.5%)	<0.001
PaO2:FiO2 ratio < 300	1,905 (34.1%)	3,075 (31.5%)	1,952 (23.9%)	6,932 (29.5%)	<0.001
Multiple organ	1 062 (19 0%)	1 200 (12 3%)	560 (6.9%)	2 822 (12 0%)	<0 001
dysfunction or failure	1,002 (10.070)	1,200 (12.070)		2,022 (121070)	
Septic shock	844 (15.1%)	960 (9.8%)	475 (5.8%)	2,279 (9.7%)	<0.001
Number of Severe Risk					<0.001
Factors	4 407 (00 10)		E 004 (00 E01)	44,000 (00, 50()	
	1,407 (20.1%)	5,085 (34.3%)	5,331 (39.5%)	11,823 (33.5%)	
	3,895 (55.7%)	6,992 (47.1%)	6,190 (45.9%)	17,077 (48.3%)	
iviany (5+)	1,000 (24.1%)	2,769 (18.7%)	1,965 (14.6%)	6,422 (18.2%)	

Table 1. Patient Characteristics Stratified by Time Period of COVID-19 Convalescent Plasma Transfusion.								
	Apr 04 - May 01 (N=6,990)	May 01 - Jun 04 (N=14,846)	Jun 04 - Jul 04 (N=13,486)	Total Patients (N=35,322)	P value			
Medications during hospital stay								
Angiotensin Receptor Blocker	397 (5.7%)	839 (5.7%)	779 (5.8%)	2,015 (5.7%)	0.90			
Ace Inhibitor	467 (6.7%)	1,130 (7.6%)	1,023 (7.6%)	2,620 (7.4%)	0.032			
Azithromycin	3,811 (54.5%)	5,717 (38.5%)	5,456 (40.5%)	14,984 (42.4%)	<0.001			
Remdesivir	329 (4.7%)	4,066 (27.4%)	6,240 (46.3%)	10,635 (30.1%)	<0.001			
Steroids	3,736 (53.4%)	6,137 (41.3%)	7,735 (57.4%)	17,608 (49.8%)	<0.001			
Chloroquine	33 (0.5%)	22 (0.1%)	6 (0.0%)	61 (0.2%)	<0.001			
Hydroxychloroquine	4,356 (62.3%)	2,437 (16.4%)	245 (1.8%)	7,038 (19.9%)	<0.001			
Time to Transfusion					<0.001			
0 days	141 (2.0%)	598 (4.0%)	625 (4.6%)	1,364 (3.9%)				
1 to 3 days	1,590 (22.7%)	5,748 (38.7%)	6,705 (49.7%)	14,043 (39.8%)				
4 to 10 days	2,843 (40.7%)	6,244 (42.1%)	5,271 (39.1%)	14,358 (40.6%)				
11+ days	2,416 (34.6%)	2,256 (15.2%)	885 (6.6%)	5,557 (15.7%)				

^aThese data include a subset of the sample (n = 23,502), only those patients that currently have severe or life-threatening COVID-19 Data was not available for Gender (n=83), Weight Status (n=1,306) and Mechanical Ventilation prior to infusion (n=544).

		Seve	n-day Mortality			Thir	y-day Mortality	
	Sample, No	Events, No	Estimate, 95% CI	P-value	Sample, No	Events, No	Estimate, 95% Cl	P-value
Overall Mortality	35,322	3,706	10.5% (10.2%, 10.8%)		35,322	8,652	24.5% (24.0%, 24.9%)	
Age				<0.0001				<0.0001
18 - 39 y	3,472	109	3.1% (2.6%, 3.8%)		3,472	261	7.5% (6.7%, 8.4%)	
40 - 59 y	12,168	662	5.4% (5.1%, 5.9%)		12,168	1,837	15.1% (14.5%, 15.7%)	
60 - 69 y	8,968	897	10.0% (9.4%, 10.6%)		8,968	2,431	27.1% (26.2%, 28.0%)	
70 - 79 у	6,704	1,023	15.3% (14.4%, 16.1%)		6,704	2,367	35.3% (34.2%, 36.5%)	
80 y or older	4,010	1,015	25.3% (24.0%, 26.7%)		4,010	1,756	43.8% (42.3%, 45.3%)	
On Ventilator Prior to Infusion				<0.0001				<0.0001
No	25,205	1,932	7.7% (7.3%, 8.0%)		25,205	4,523	17.9% (17.5%, 18.4%)	
Yes	9,573	1,685	17.6% (16.9%, 18.4%)		9,573	3,924	41.0% (40.0%, 42.0%)	
Missing	544	89	16.4% (13.5%, 19.7%)		544	205	37.7% (33.7%, 41.8%)	
Days to Transfusion				<0.0001				<0.0001
<= 3 days	15,407	1,340	8.7% (8.3%, 9.2%)		15,407	3,329	21.6% (21.0%, 22.3%)	
4+ days	19,915	2,366	11.9% (11.4%, 12.3%)		19,915	5,323	26.7% (26.1%, 27.3%)	
Study Period and Days to Transfusion	ו			<0.0001				<0.0001
Apr 04 - May 01 (<= 3 days)	1,731	232	13.4% (11.9%, 15.1%)		1,731	526	30.4% (28.3%, 32.6%)	
Apr 04 - May 01 (4+ days)	5,259	853	16.2% (15.2%, 17.2%)		5,259	1,821	34.6% (33.4%, 35.9%)	
May 01 - Jun 04 (<= 3 days)	6,346	659	10.4% (9.7%, 11.2%)		6,346	1,452	22.9% (21.9%, 23.9%)	
May 01 - Jun 04 (4+ days)	8,500	1,060	12.5% (11.8%, 13.2%)		8,500	2,260	26.6% (25.7%, 27.5%)	
Jun 04 - Jul 04 (<= 3 days)	7,330	449	6.1% (5.6%, 6.7%)		7,330	1,351	18.4% (17.6%, 19.3%)	
Jun 04 - Jul 04 (4+ days)	6,156	453	7.4% (6.7%, 8.0%)		6,156	1,242	20.2% (19.2%, 21.2%)	
Ortho IgG				0.0483				0.0208
Low	561	77	13.7% (11.1%, 16.8%)		561	166	29.6% (26.0%, 33.5%)	
Medium	2,006	233	11.6% (10.3%, 13.1%)		2,006	549	27.4% (25.5%, 29.4%)	
High	515	46	8.9% (6.8%, 11.7%)		515	115	22.3% (18.9%, 26.1%)	
IgG - Time to Transfusion				0.0500				<0.0001
<= 3 days (Low)	190	25	13.2% (9.1%, 18.7%)		190	48	25.3% (19.6%, 31.9%)	
<= 3 days (Medium)	727	73	10.0% (8.1%, 12.4%)		727	166	22.8% (19.9%, 26.0%)	
<= 3 days (High)	180	11	6.1% (3.4%, 10.6%)		180	30	16.7% (11.9%, 22.8%)	
4+ days (Low)	371	52	14.0% (10.9%, 17.9%)		371	118	31.8% (27.3%, 36.7%)	
4+ days (Medium)	1,279	160	12.5% (10.8%, 14.4%)		1,279	383	29.9% (27.5%, 32.5%)	
4+ days (High)	335	35	10.4% (7.6%, 14.2%)		335	85	25.4% (21.0%, 30.3%)	



507

508 Figure 1. Participation in the US COVID-19 Convalescent Plasma Expanded Access 509 Program (EAP). A. Choropleth map displaying the number of cumulatively enrolled patients in 510 the EAP within each state of the contiguous US, with lower enrollment values displayed in a 511 lighter hue and higher enrollment values displayed in a darker hue of blue. Registered acute 512 care facilities are represented as filled yellow circles, with larger circles indicating greater 513 number of registered facilities within the metropolitan area of a city. The choropleth map does 514 not display data from non-contiguous US locations, including registered facilities in Puerto Rico, 515 Hawaii, Alaska, Guam, and Northern Mariana Islands. B. The chronological graph represents 516 the number of patients that have received a COVID-19 convalescent plasma transfusion, 517 including daily counts (blue bars) and 7-day average (blue line). The dashed vertical reference 518 lines delineate the three study epochs.



519

520 Figure 2. Seven day (A, B) and 30-day (C, D) adjusted mortality stratified by antibody 521 groupings in patients transfused with COVID-19 convalescent plasma. Adjusted mortality 522 rate is presented on the vertical axis, and the height of each bar graph represents adjusted 523 mortality with 95% confidence interval denoted. Data are stratified by groupings of antibody 524 levels with semiquantitative groupings of low (<4.62 S/Co, orange bars), medium (4.62 to 18.45 525 S/Co, blue bars) and high (> 18.45 S/Co, green bars). Values presented as text within the boxes 526 are the estimated adjusted mortality rates. Values connecting various categories shown with the 527 overbraces are bootstrapped estimates of relative risk and 95% bootstrap confidence intervals. 528 Refer to the methods for the variables in the adjustment and the calculation of the relative risks.





B. 30-Day Mortality

530 Figure 3. Forest plots of relative risks for 7-day (A) and 30-day (B) mortality for high 531 versus low antibody concentration. Each row in the figure represents 10 mutually exclusive 532 categorizations of patients transfused with convalescent plasma with measured antibody levels. 533 Estimates are the relative risk for mortality for patients who received convalescent plasma with 534 IgG S/co > 18.45 vs. patients that received < 4.62 S/Co. Patients that received units with IgG535 S/Co values between 4.62 and 18.45 are not included in this analysis as the planned 536 comparison was to highlight the potential efficacy of high IgG containing units vs. units with low 537 levels of detectable antibodies. The bottom row in each figure represents the common (pooled) 538 estimate based on the Mantel-Haenszel estimator. The number of severe risk factors was 539 categorized as none (n=0), limited (n=1-4) or many (5 or more), as defined in **Table 1**.

540

541	Supplement 1

542

Trial Protocol

543 **1 | Study Objectives**

544 Convalescent plasma is a potential disease altering therapy for hospitalized patients 545 with COVID-19 infections. There is strong historical precedence for its use in respiratory 546 infections suggesting it may be effective in the treatment of COVID-19. Additionally, the 547 administration of convalescent plasma is considered well-tolerated and safe, both 548 historically and within the context of the current COVID-19 pandemic.

549 1.2 | Primary Objectives

550 The primary outcome of this Expanded Access Program was to provide access to 551 COVID-19 convalescent plasma, assessed as the availability of convalescent plasma.

552 **1.3 | Secondary Objectives**

553 The secondary outcome of this Expanded Access Program was to determine the safety 554 of transfusion of COVID-19 convalescent plasma assessed as the case-rate and 555 relatedness of serious adverse events.

556 **1.4 | Tertiary Objectives**

557 The tertiary outcome of this Expanded Access Program was to explore the efficacy of 558 transfusion of COVID-19 convalescent plasma.

559 2 | Study Intervention

- This Expanded Access Program was a national, pragmatic intervention conducted as a
 multicenter, open-label protocol in hospitalized adults with COVID-19. All patients
 received the study intervention (COVID-19 convalescent plasma transfusion). Primary
 study endpoints included:
 - **1.** Hospital discharge
 - 2. Death
 - 3. 30 days of observation after COVID-19 convalescent plasma transfusion
- 566 567

564

565

568 2.1 | Study Intervention Description

569 Compatible COVID-19 convalescent plasma was administered intravenously according 570 to accepted transfusion guidelines used for fresh frozen plasma.

571 **2.2 | Dosing and Administration**

572 For practical purposes in the current outbreak, one – two units of compatible COVID-19 573 convalescent plasma were administered. Convalescent plasma was obtained from a 574 registered or licensed blood collector and was collected preferably by apheresis or, if 575 necessary, by conventional methods. Individual institutional guidelines for the 576 administration of plasma were followed, including the use of any premedications, such 577 as acetaminophen or diphenhydramine.

578 **2.3 | Preparation and Packaging**

579 Compatible convalescent plasma units were obtained from a registered or licensed 580 blood collector following registration of a patient under the auspices of the Expanded 581 Access Program. COVID-19 convalescent plasma was supplied as an investigational 582 blood product for the treatment of COVID-19. The plasma container label of the COVID-583 19 convalescent plasma unit included the following statement, "Caution: New Drug – 584 Limited by Federal (or United States) law to investigational use." (21 CFR 312.6(a)).

585 3 | Research Population

586 Eligible patients for this Expanded Access Program were identified by their treating 587 providers. The patient inclusion criteria were specific to hospitalized patients, these 588 criteria were exceptionally broad.

589 3.1 | Inclusion Criteria

Supplemental Table 1. Inclusion Criteria

- 1. Age at least 18 years
- 2. Laboratory confirmed diagnosis of infection with SARS-CoV-2
- **3.** Admitted to an acute care facility for the treatment of COVID-19 complications
- 4. Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease
- **5.** Informed consent provided by the patient or healthcare proxy

Severe or Life-threatening COVID-19 is defined by one or more of the following:

- dyspnea
- respiratory frequency $\geq 30 \cdot \min^{-1}$
- blood oxygen saturation $\leq 93\%$
- partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300
- lung infiltrates > 50% within 24 to 48 hours
- respiratory failure
- septic shock
- multiple organ failure

590

591 3.2 | Exclusion Criteria

592 None.

593 594

Supplement 2

Supplemental Table 2. F	Patient Characteristi	cs Stratified by IgG.			
	Low (N=561)	Medium (N=2,006)	High (N=515)	Total Patients (N=3,082)	P value
Age at Enrollment					0.078
(years)					0.070
18 to 39	59 (10.5%)	155 (7.7%)	53 (10.3%)	267 (8.7%)	
40 to 59	185 (33.0%)	689 (34.3%)	183 (35.5%)	1,057 (34.3%)	
60 to 69	152 (27.1%)	503 (25.1%)	143 (27.8%)	798 (25.9%)	
70 to 79	102 (18.2%)	418 (20.8%)	86 (16.7%)	606 (19.7%)	
80 or older	63 (11.2%)	241 (12.0%)	50 (9.7%)	354 (11.5%)	
Gender					0.14
Female	201 (36.0%)	774 (38.7%)	221 (42.9%)	1,196 (38.9%)	
Male	357 (63.9%)	1,227 (61.3%)	293 (56.9%)	1,877 (61.0%)	
Undisclosed	1 (0.2%)	1 (0.0%)	1 (0.2%)	3 (0.1%)	
Weight Status					0.064
Underweight	7 (1.4%)	32 (1.7%)	3 (0.6%)	42 (1.5%)	
Normal Weight	87 (17.0%)	334 (17.7%)	84 (17.1%)	505 (17.5%)	
Overweight	154 (30.1%)	545 (28.8%)	115 (23.5%)	814 (28.1%)	
Obese	263 (51.5%)	980 (51.8%)	288 (58.8%)	1,531 (52.9%)	
Race					0.54
White	266 (47.4%)	967 (48.2%)	234 (45.4%)	1,467 (47.6%)	
Asian	23 (4.1%)	77 (3.8%)	15 (2.9%)	115 (3.7%)	
Black or African					
American	125 (22.3%)	443 (22.1%)	135 (26.2%)	703 (22.8%)	
Other or Unknown	147 (26.2%)	519 (25.9%)	131 (25.4%)	797 (25.9%)	
Ethnicity					0.24
Hispanic/Latino	223 (39.8%)	747 (37.2%)	179 (34.8%)	1,149 (37.3%)	
Not Hispanic/Latino	338 (60.2%)	1,259 (62.8%)	336 (65.2%)	1,933 (62.7%)	
Severe Risk Factors					
Current severe or					
life-threatening COVID-19	382 (68.1%)	1,286 (64.1%)	341 (66.2%)	2,009 (65.2%)	0.19
Intensive Care Unit					
(ICU) care prior to	344 (61.3%)	1,226 (61.1%)	298 (57.9%)	1,868 (60.6%)	0.38
infusion					
Mechanical					
Ventilation prior to	183 (33.4%)	666 (33.9%)	158 (31.0%)	1,007 (33.3%)	0.45
infusion					
Clinical symptoms ^a					
Respiratory failure	265 (69.4%)	919 (71.5%)	231 (67.7%)	1,415 (70.4%)	0.36
Dyspnea	265 (69.4%)	910 (70.8%)	241 (70.7%)	1,416 (70.5%)	0.87
Blood oxygen	260 (70 4%)	000 (70 7%)	233 (68 3%)	1 /11 (70 2%)	0.70
saturation ≤ 93%	209 (70.476)	909 (70.776)	233 (00.376)	1,411 (70.276)	0.70
Lung infiltrates >					
50% within 24 to 48	194 (50.8%)	588 (45.7%)	147 (43.1%)	929 (46.2%)	0.097
hours					
Respiratory	177 (46.3%)	580 (45.1%)	157 (46.0%)	914 (45.5%)	0.89
frequency ≥ 30/min			101 (101070)		0.00
PaO2:FiO2 ratio <	137 (35.9%)	451 (35.1%)	93 (27.3%)	681 (33.9%)	0.017
300	. /	· /	· /	. /	

Supplemental Table 2. P	Patient Characteristi	cs Stratified by IgG.			
	Low (N=561)	Medium (N=2,006)	High (N=515)	Total Patients (N=3,082)	P value
Multiple organ dysfunction or failure	65 (17.0%)	227 (17.7%)	48 (14.1%)	340 (16.9%)	0.29
Septic shock	56 (14.7%)	188 (14.6%)	44 (12.9%)	288 (14.3%)	0.71
Number of Severe Risk Factors					0.042
None	179 (31.9%)	720 (35.9%)	174 (33.8%)	1,073 (34.8%)	
Limited (1 to 4)	239 (42.6%)	868 (43.3%)	243 (47.2%)	1,350 (43.8%)	
Many (5+)	143 (25.5%)	418 (20.8%)	98 (19.0%)	659 (21.4%)	
Medications during hospital stay					
ARB	27 (4.8%)	107 (5.3%)	24 (4.7%)	158 (5.1%)	0.77
Ace Inhibitor	40 (7.1%)	175 (8.7%)	35 (6.8%)	250 (8.1%)	0.23
Azithromycin	277 (49.4%)	923 (46.0%)	226 (43.9%)	1,426 (46.3%)	0.18
Remdesivir	164 (29.2%)	538 (26.8%)	130 (25.2%)	832 (27.0%)	0.32
Steroids	251 (44.7%)	899 (44.8%)	209 (40.6%)	1,359 (44.1%)	0.21
Chloroquine	4 (0.7%)	4 (0.2%)	1 (0.2%)	9 (0.3%)	0.12
Hydroxychloroquine	174 (31.0%)	595 (29.7%)	99 (19.2%)	868 (28.2%)	<0.001
Time to Transfusion					0.34
0 days	16 (2.9%)	58 (2.9%)	16 (3.1%)	90 (2.9%)	
1 to 3 days	174 (31.0%)	669 (33.3%)	164 (31.8%)	1,007 (32.7%)	
4 to 10 days	251 (44.7%)	846 (42.2%)	244 (47.4%)	1,341 (43.5%)	
11+ days	120 (21.4%)	433 (21.6%)	91 (17.7%)	644 (20.9%)	
Time Epoch					<0.001
Apr 04 to May 01	146 (26.0%)	543 (27.1%)	86 (16.7%)	775 (25.1%)	
May 01 to Jun 04	348 (62.0%)	1,242 (61.9%)	359 (69.7%)	1,949 (63.2%)	
Jun 04 to Jul 04	67 (11.9%)	221 (11.0%)	70 (13.6%)	358 (11.6%)	

^aThese data include a subset of the sample (n = 2,009), only those patients that currently have severe or life-threatening COVID-19

Data was not available for Gender (n=6), Weight Status (n=190) and Mechanical Ventilation prior to infusion (n=61).

595

Supplemental Table 3. Crude Mortality (7 and 30 day) of patients with IgG transfused with COVID-10 Convalescent Plasma.							na.	
	Seven-day Mortality Thirty-day Mortality			y-day Mortality				
	Sample, No	Events, No	Estimate, 95% CI	P-value	Sample, No	Events, No	Estimate, 95% CI	P-value
Overall Mortality	3,082	356	11.6% (10.5%, 12.7%)		3,082	830	26.9% (25.4%, 28.5%)	
Age				<0.0001				<0.0001
18 - 39 y	267	10	3.7% (2.0%, 6.8%)		267	27	10.1% (7.0%, 14.3%)	
40 - 59 y	1,057	83	7.9% (6.4%, 9.6%)		1,057	187	17.7% (15.5%, 20.1%)	
60 - 69 y	798	89	11.2% (9.2%, 13.5%)		798	243	30.5% (27.4%, 33.7%)	
70 - 79 y	606	97	16.0% (13.3%, 19.1%)		606	217	35.8% (32.1%, 39.7%)	
80 y or older	354	77	21.8% (17.8%, 26.3%)		354	156	44.1% (39.0%, 49.3%)	
On Ventilator Prior to Infusion				<0.0001				<0.0001
No	2,014	170	8.4% (7.3%, 9.7%)		2,014	382	19.0% (17.3%, 20.7%)	
Yes	1,007	177	17.6% (15.4%, 20.0%)		1,007	421	41.8% (38.8%, 44.9%)	
Missing	61	9	14.8% (8.0%, 25.7%)		61	27	44.3% (32.5%, 56.7%)	
Days to Transfusion				0.0371				<0.0001
<= 3 days	1,097	109	9.9% (8.3%, 11.8%)		1,097	244	22.2% (19.9%, 24.8%)	
4+ days	1,985	247	12.4% (11.1%, 14.0%)		1,985	586	29.5% (27.6%, 31.6%)	
Study Period and Days to Transfusion				0.0470				<0.0001
Apr 04 - May 01 (<= 3 days)	138	14	10.1% (6.1%, 16.3%)		138	36	26.1% (19.5%, 34.0%)	
Apr 04 - May 01 (4+ days)	637	95	14.9% (12.4%, 17.9%)		637	219	34.4% (30.8%, 38.2%)	
May 01 - Jun 04 (<= 3 days)	773	77	10.0% (8.0%, 12.3%)		773	172	22.3% (19.5%, 25.3%)	
May 01 - Jun 04 (4+ days)	1,176	137	11.6% (9.9%, 13.6%)		1,176	327	27.8% (25.3%, 30.4%)	
Jun 04 - Jul 04 (<= 3 days)	186	18	9.7% (6.2%, 14.8%)		186	36	19.4% (14.3%, 25.6%)	
Jun 04 - Jul 04 (4+ days)	172	15	8.7% (5.4%, 13.9%)		172	40	23.3% (17.6%, 30.1%)	
Ortho IgG				0.0483				0.0208
Low	561	77	13.7% (11.1%, 16.8%)		561	166	29.6% (26.0%, 33.5%)	
Medium	2,006	233	11.6% (10.3%, 13.1%)		2,006	549	27.4% (25.5%, 29.4%)	
High	515	46	8.9% (6.8%, 11.7%)		515	115	22.3% (18.9%, 26.1%)	
IgG - Time to Transfusion				0.0500				<0.0001
<= 3 days (Low)	190	25	13.2% (9.1%, 18.7%)		190	48	25.3% (19.6%, 31.9%)	
<= 3 days (Medium)	727	73	10.0% (8.1%, 12.4%)		727	166	22.8% (19.9%, 26.0%)	
<= 3 days (High)	180	11	6.1% (3.4%, 10.6%)		180	30	16.7% (11.9%, 22.8%)	
4+ days (Low)	371	52	14.0% (10.9%, 17.9%)		371	118	31.8% (27.3%, 36.7%)	
4+ days (Medium)	1,279	160	12.5% (10.8%, 14.4%)		1,279	383	29.9% (27.5%, 32.5%)	
4+ days (High)	335	35	10.4% (7.6%, 14.2%)		335	85	25.4% (21.0%, 30.3%)	

596